Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease

ConclusionThis case series demonstrates significantly reduced number of endoscopies and increased bleed‐free duration with lenalidomide treatment in selected patients with VWD and recurrent GIB from AD. Prospective multicenter trials are needed to further define the role of lenalidomide in the management of GIB from angiodysplasia and VWD.

Source: Haemophilia - February 1, 2018 Category: Hematology Authors: N. V. Khatri, B. Patel, D. R. Kohli, S. S. Solomon, K. Bull ‐Henry, C. M. Kessler Tags: ORIGINAL ARTICLE Source Type: research